Author: MA

Curapath is pleased to acknowledge the significant progress achieved by Macro Biologics, Inc., whose IND application for Amicidin‑α Surgical Gel has been accepted by the FDA, enabling the initiation of the Phase 1 clinical trial. This milestone marks a decisive step in the evolution of the Amicidin‑α platform toward clinical

Curapath has partnered with Nacalai Tesque to expand access to its portfolio of next-generation polymers and PEG-free shielding lipids for advanced drug delivery applications in Japan. This collaboration strengthens Curapath’s global presence and enables local availability of high-quality excipients for researchers and biopharma companies working on non-viral delivery technologies. Through

Over the past two decades, polymer-based drug delivery systems have evolved from experimental concepts to clinically validated technologies, playing a key role in the development of next-generation therapeutics. At Curapath, with over 13 years of hands-on expertise, we support biotech and pharmaceutical companies with polymer and lipid-based solutions, from early